**AUB KQ1 Evidence Table (Reference ID #1116)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality**  **Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**  Cameron et al., 1990  **Country:**  United Kingdom  **Enrollment** **period:**  NR  **Intervention** **setting:**  Outpatient department  **Funding:**  Parke-Davis Research Laboratories, Eastleigh, UK  **Author industry relationship disclosures:**  NR  **Study Design:**  RCT  **Blinding:**  NR | **Intervention:**  Mefenamic acid, 500 mg three times daily on days 1-5 of menses  **Comparator:**  Norethisterone, 5 mg twice daily on cycle days 19-26  **Groups:**  **G1:** Mefenamic acid  **G2:** Norethisterone  2 control cycles  Cycle 1  Cycle 2  2 treatment cycles  Cycle 3  Cycle 4 | **Inclusion criteria:**  Heavy menstruation defined by average MBL >80 ml per cycle  **Exclusion criteria:**  Organic disease  Receiving medical treatment for menorrhagia  **N at enrollment:**  **G1:** 17  **G2:** 15  **N at followup:**  **G1:** 17  **G2:**15  **Age, median years (range):**  **G1:** 40 (27, 48)  **G2:** 40 (21, 51)  **BMI:**  NR  **Height, median cm (range):**  **G1:** 163 (154, 177)  **G2:** 163 (150, 181)  **Weight, median kg (range):**  **G1:** 67 (52, 92)  **G2:** 65 (48, 102)  **Parity:**  NR  **Race/ethnicity:**  NR | **Bleeding:**  MBL measured by alkaline hematin method, median ml (range):  **G1:** 123 (86, 237)  **G2:** 109 (81, 236)  Duration at cycle 1, median days (range):  **G1:** 7 (5, 8)  **G2:** 7 (5, 10)  Duration at cycle 2, median days (range):  **G1:** 6 (4, 9)  **G2:** 6 (4, 9)  Cycle length at cycle 1, median days (range):  **G1:** 28 (21, 35)  **G2:** 28 (21, 35)  Cycle length at cycle 2, median days (range):  **G1:** 27 (21, 33)  **G2:** 29 (21, 31**)** | **Bleeding:**  MBL measured by alkaline hematin method, median ml (range):  **G1:** 81 (22, 193)  **G2:** 92 (43, 189)  **G1 vs. BL:** p<0.001  **G2 vs. BL:** p<0.002  MBL change, median % (range):  **G1:** -24 (-83, 5)  **G2:** -20 (-53, 2)  **G1 vs. G2:** p>0.1  Duration at cycle 3, median days (range):  **G1:** 6 (5, 9)  **G2:** 6 (4, 8)  Duration at cycle 4, median days (range):  **G1:** 5 (3, 8)  **G2:** 6 (4, 8)  **G1 vs. BL:** p<0.01  **G2 vs. BL:** p=NS  Cycle length at cycle 3, median days (range):  **G1:** 27 (25, 37)  **G2:** 29 (28, 32)  Cycle length at cycle 4, median days (range):  **G1:** 28 (25, 32)  **G2:** 29 (26, 35)  **G1 vs. BL:** p=NS  **G2 vs. BL:** p=NS  **Quality of life:**  NR  **Pain, n (%):**  Abdominal pain:  **G1:** 3 (18)  **G2:** 3 (20)  Headache:  **G1:** 4 (24)  **G2:** 5 (33)  **Sexual function:**  NR  **Patient satisfaction:**  NR  **Fertility:**  NR  **Time to conception:**  NR  **Additional interventions:**  NR  **Adverse events, n (%):**  Any side effect:  **G1:** 10 (59)  **G2:** 9 (60)  Nausea:  **G1:** 2 (12)  **G2:** 1 (7)  Othera:  **G1:** 2 (12)  **G2:** 1 (7) | **Overall quality:** Poor  **Risk of bias:**  Randomization:  Unclear  Allocation concealment:  Unclear  Selective reporting:  Low  Blinding patients/personnel:  Unclear  Blinding outcome assessment:  Unclear  Incomplete outcome reporting:  Low  Other:  Low |

**Table Notes:** a Not including abdominal pain or headache.